Huntingdon Life Sciences acquires Harlan Laboratories

Published: 2-May-2014
Research & Development Finance

Creates a leading global contract organisation


Huntingdon Life Sciences, a UK-based contract research organisation, has bought Harlan Laboratories for an undisclosed sum.

The combined company will have two operating divisions: Research Models and Services and Contract Research Services. It will have revenue of around US$500m, providing a strong platform for future growth.

The acquisition creates a leading global organisation offering full service, non-clinical, contract research and research models and services, the company said.

Brian Cass, CEO of Huntingdon Life Sciences, said: 'This acquisition is precisely in line with our strategy to broaden our support for the pharmaceutical, crop protection and chemical industries, as well as universities, government, and other research organisations. Our two companies have a long heritage and together we will maintain and build on our reputation for high quality science and innovation.'

Harlan CEO Hans Thunem added: 'Merging these two leading companies, with their complementary product and service offerings, positions the combined organisation as a global leader in supporting the growing market for outsourced research and development.'

  • Companies:
  • Envigo
See more

You may also like

Manufacturing

(Cryo)preserving your research

Read more
Bringing welfare, logistical and cost benefits to modern preclinical drug development studies

Trending Articles

  1. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  2. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  5. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

(Cryo)preserving your research

Bringing welfare, logistical and cost benefits to modern preclinical drug development studies
Research & Development

In vivo models to target respiratory diseases

Envigo’s Steve Jordan offers intuitive analysis and insights into methods of optimising in vivo efficacy studies and predicts what developments might be coming to fruition in the future
Regulatory

Successful AAALAC accreditation for Envigo facilities in Barcelona, Spain

Envigo has announced that its contract research facilities in Barcelona, Spain have been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council
Research & Development

Envigo launches hepatotoxicity testing to drug development derisking programme

Envigo announces the launch of an integrated programme of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI) – one of the major causes of drugs being withdrawn from the market
Research & Development

Envigo invests in Science and Technology Advisory Group (STAG)

STAG will act as an internal funding body for promising research, develop new assays and technologies with customers
Research & Development

Envigo opens its doors for business

The firm has been formed as a result of the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR
Research & Development

Huntingdon Life Sciences and Harlan announce new equity funding

The combined company, soon to be called Envigo, has received a commitment of up to US$125m in minority equity financing
Subscribe now